https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-20 / Cancers (Basel) 2021 May;13(10)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-20 / Cancers (Basel) 2021 May;13(10)2021-05-20 00:00:002021-05-20 00:00:00Recent Progress in Dendritic Cell-Based Cancer Immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-19 / Mol Ther Oncolytics 2021 Sep;22:64-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-19 / Mol Ther Oncolytics 2021 Sep;22:64-712021-05-19 00:00:002021-05-19 00:00:00CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-19 / Vaccines (Basel) 2021 May;9(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-19 / Vaccines (Basel) 2021 May;9(5)2021-05-19 00:00:002021-05-19 00:00:00Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-14 / Ther Apher Dial 2021 Aug;25(4):415-424
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-14 / Ther Apher Dial 2021 Aug;25(4):415-4242021-05-14 00:00:002023-01-31 12:56:12Dendritic cell vaccination combined with a conventional chemotherapy for patients with relapsed or advanced pancreatic ductal adenocarcinoma: a single-center phase I/II trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-12 / Cancer Med 2021 Jul;10(13):4302-4311
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-12 / Cancer Med 2021 Jul;10(13):4302-43112021-05-12 00:00:002021-08-09 09:14:27Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-05-10 / Front Oncol 2021;11:672508
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-05-10 / Front Oncol 2021;11:6725082021-05-10 00:00:002021-05-10 00:00:00Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-04-06 / J Gynecol Oncol 2021 Jul;32(4):e59
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-04-06 / J Gynecol Oncol 2021 Jul;32(4):e592021-04-06 00:00:002021-04-06 00:00:00Autologous cervical tumor lysate pulsed dendritic cell stimulation followed by cisplatin treatment abrogates FOXP3+ cells in vitro
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-03-29 / Front Immunol 2021;12:641307
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-03-29 / Front Immunol 2021;12:6413072021-03-29 00:00:002021-03-29 00:00:00Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-03-10 / Int J Mol Sci 2021 Mar;22(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-03-10 / Int J Mol Sci 2021 Mar;22(6)2021-03-10 00:00:002021-03-10 00:00:00Cell Therapies in Bladder Cancer Management
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2021-02-27 / Ann Surg Oncol 2021 Oct;28(11):6126-6137
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2021-02-27 / Ann Surg Oncol 2021 Oct;28(11):6126-61372021-02-27 00:00:002021-02-27 00:00:00A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
